New malaria pill shows promise in early trial

NCT ID NCT07545681

Not yet recruiting Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This phase 2 study tests a new antimalarial drug called GSK3772701 in 70 adults with uncomplicated P. falciparum malaria. Participants receive different doses for 1 to 3 days to see if it is safe and clears the parasite. The goal is to find a new treatment option that could work against drug-resistant malaria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK3772701 (a pyrrolidinamide antimalarial drug)
What this could lead to: If successful, this could provide a new treatment option for uncomplicated malaria, potentially helping to overcome drug resistance.
What could go wrong: This is an early phase 2 trial with only 70 participants, so results may not apply to everyone. The drug may cause side effects or fail to clear the infection effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA,FALCIPARUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria Plasmodium falciparum malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA,FALCIPARUM

More trials for these conditions

Other studies related to the condition(s) this trial covers.